Medical technology company iSonea has initiated a US post-market study of its WheezoMeter monitoring technology in paediatric patients with a range of asthma symptom severity.
The Wheeze Rate Correlation Study is expected to include around 95 participants in Folsom in California, US, to evaluate wheeze rate in paediatric asthma patients who are too young to be tested with spirometry, a traditional measuring technique used in older children and adults.
The WheezoMeter analyses 30 seconds of breathing sounds using advanced signal processing algorithms to detect, quantify and objectively document the presence of wheeze and its extent.
The asthma monitoring device is based on the company’s Acoustic Respiratory Monitoring (ARM) technology platform, which uses acoustic sensors and signal processing software to record the presence, frequency and severity of wheezing. The portable WheezoMeter employs a cascade of six proprietary technologies to defend the signals against false detection of ambient noises, and enables frequent monitoring in real-life settings.
Jonathan Freudman, iSonea medical director, said asthma impacts more than seven million children in the US, and the number of children expected to be diagnosed with the chronic condition continues to increase at alarming rates.
"In the pediatric asthma population, it is challenging to accurately monitor and manage asthma symptoms in patients using conventional techniques," Freudman added.
"The WheezoMeter has the potential to meet a critical unmet need for better, easy to use monitoring tools for young asthma patients."
By using ARM technology with the company’s AsthmaSense mobile applications, iSonea is turning smartphones into medical devices enabling anyone, anywhere, at anytime to monitor breathing distress symptoms.
Medical technology company iSonea develops innovative, non-invasive devices and mobile health applications to improve the management of chronic respiratory disorders, such as asthma and chronic obstructive pulmonary disease (COPD).